Platelets by Cell Separator at Chughtai Lab

Platelets by Cell Separator at Chughtai Lab

Platelets by Cell Separator, clinically referred to as plateletpheresis or Single Donor Platelets (SDP), is a highly specialized and advanced blood banking procedure designed to harvest a high concentration of platelets from a single healthy donor. Unlike random donor platelets (RDP) which are pooled from multiple whole blood donations, a single donor platelet unit obtained via a cell separator provides a therapeutic dose equivalent to six units of random platelets. This state-of-the-art procedure is performed at Chughtai Lab, Pakistan’s premier diagnostic and laboratory network, utilizing cutting-edge automated apheresis technology. By utilizing a closed, sterile, and automated system, Chughtai Lab ensures the highest standards of safety, quality, and efficacy for both the donor and the recipient. The primary objective of this procedure is to support patients suffering from severe thrombocytopenia, active hemorrhage, or those undergoing intensive oncological treatments where platelet counts drop to life-threatening levels.

The technology behind the cell separator involves a continuous-flow centrifugation process. During the procedure, whole blood is drawn from the donor’s vein and channeled into a sterile, single-use disposable kit installed within the apheresis machine. The machine centrifuges the blood to separate its individual components based on their specific gravity. Platelets, along with a minimal volume of plasma, are selectively diverted into a collection bag, while the remaining cellular components—including red blood cells, white blood cells, and the majority of the plasma—are safely reinfused back into the donor. This selective extraction allows donors to donate a significant volume of platelets without compromising their overall blood volume or red blood cell count, making it possible to donate platelets more frequently than whole blood. Chughtai Lab’s commitment to clinical excellence ensures that every step of this automated process is monitored by qualified hematologists and trained transfusion specialists.

Clinical Procedure: What to Expect

The Platelets by Cell Separator procedure at Chughtai Lab is a highly coordinated process designed to ensure the safety of the donor while securing a high-quality therapeutic product for the patient. Understanding the steps involved can help alleviate any anxiety and ensure a smooth, comfortable experience for both the donor and the patient’s family.

Patient and Donor Preparation

• Medication Restrictions: Donors must strictly avoid taking aspirin, products containing aspirin, or non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen for at least 72 hours before donation. These medications temporarily impair platelet function, rendering the collected product ineffective for the recipient.
• Hydration and Nutrition: Donors should drink plenty of water or non-alcoholic fluids starting 24 hours before the procedure. Eating a healthy, low-fat meal before the donation is highly recommended to prevent lightheadedness and maintain stable blood lipid levels, which prevents interference with the machine’s optical sensors.
• Rest: Getting a good night’s sleep (7-8 hours) before the donation day is crucial for maintaining hemodynamic stability.
• Pre-donation Screening: Upon arrival at Chughtai Lab, the donor undergoes a comprehensive physical evaluation, including blood pressure, pulse, temperature, and weight checks. A small blood sample is drawn to verify the donor’s hemoglobin level (minimum 12.5 g/dL) and pre-donation platelet count (minimum 150,000/µL).
• Infectious Disease Testing: The donor’s blood is screened for transfusion-transmitted infections, including HIV, Hepatitis B, Hepatitis C, Syphilis, and Malaria, using advanced laboratory assays to guarantee recipient safety.

During the Procedure

• Positioning: The donor is comfortably seated in a reclining apheresis chair designed to facilitate relaxation during the 60 to 90-minute process.
• Venipuncture: A trained phlebotomist performs venipuncture. Depending on the specific cell separator machine used, this may involve a dual-needle system (one needle in each arm—one for drawing blood and one for returning it) or a single-needle system (alternating draw and return cycles through the same arm).
• Automated Separation: The donor’s blood flows into the sterile, single-use disposable tubing kit of the cell separator machine. The machine centrifuges the blood, separating the lighter platelet-rich plasma from the heavier red and white blood cells. The platelets are directed into a collection bag, while the remaining blood components are mixed with a small amount of saline and returned to the donor.
• Anticoagulation: An anticoagulant called Acid Citrate Dextrose (ACD) is automatically infused into the blood circuit to prevent clotting within the machine. A small amount of citrate enters the donor’s circulation, which can temporarily lower blood calcium levels. Donors are monitored for mild symptoms like tingling around the lips or fingers, which is easily managed by providing oral calcium tablets.
• Monitoring and Completion: Throughout the procedure, Chughtai Lab’s medical staff continuously monitors the donor’s vital signs and the machine’s parameters. Once the target platelet yield is achieved, the machine automatically stops, the needles are gently removed, and a sterile pressure bandage is applied to the venipuncture sites.

When is a Platelets by Cell Separator Procedure Performed?

Severe Thrombocytopenia in Oncology Patients

Oncology patients undergoing intensive chemotherapy or bone marrow transplantation often experience severe bone marrow suppression, leading to a critical drop in platelet counts (thrombocytopenia). When the platelet count falls below 10,000 to 20,000 cells per microliter, the risk of spontaneous, life-threatening internal bleeding increases exponentially. Physicians at leading medical institutions across Pakistan request Single Donor Platelets (SDP) by cell separator from Chughtai Lab to prophylactically raise the patient’s platelet levels, ensuring they can safely continue their life-saving cancer therapies without the risk of severe hemorrhagic complications.

Aplastic Anemia and Bone Marrow Failure

Aplastic anemia and other bone marrow failure syndromes result in the inadequate production of all blood cell lines, including platelets. Patients with these chronic conditions require regular supportive platelet transfusions to manage chronic bleeding manifestations such as epistaxis, hematuria, and petechiae. Transfusing platelets obtained via cell separator is highly preferred for these patients because it minimizes exposure to multiple donor antigens, thereby reducing the risk of HLA alloimmunization, a condition where the patient’s immune system develops antibodies against foreign platelets, rendering future transfusions ineffective.

Active Hemorrhage with Low Platelet Count

In acute clinical scenarios such as major trauma, massive gastrointestinal bleeding, or severe postpartum hemorrhage, rapid and effective hemostasis is critical. If the patient’s platelet count is low or if they have functional platelet defects, prompt transfusion of high-yield platelets is required. The Platelets by Cell Separator procedure at Chughtai Lab provides a highly concentrated therapeutic dose that immediately aids in clot formation at the site of vascular injury, helping clinicians stabilize the patient and control life-threatening bleeding rapidly.

Prophylaxis Before Invasive Surgical Procedures

Patients with mild to moderate thrombocytopenia who must undergo invasive surgical procedures, such as neurosurgery, cardiothoracic surgery, or even minor procedures like liver biopsies and lumbar punctures, require a safe platelet threshold to prevent intraoperative and postoperative bleeding. Surgeons typically require platelet counts to be maintained above 50,000 or 100,000 cells per microliter depending on the surgery’s complexity. Obtaining SDP from Chughtai Lab ensures that the patient’s platelet count is elevated to a safe therapeutic level immediately prior to the surgical intervention.

Refractoriness to Random Donor Platelets (RDP)

Some patients who receive multiple transfusions of random donor platelets develop platelet refractoriness, meaning their post-transfusion platelet counts do not increase as expected due to immune-mediated destruction of the transfused cells. In such cases, hematologists recommend Single Donor Platelets obtained via cell separator. This allows for HLA-matched or cross-matched platelet selections from specific donors, ensuring that the transfused platelets survive longer in the recipient’s circulation and effectively prevent or treat bleeding episodes.

What Does a Platelets by Cell Separator Procedure Detect and Evaluate?

The Platelets by Cell Separator process at Chughtai Lab involves rigorous screening, monitoring, and quality control metrics to ensure product safety and donor well-being. The procedure evaluates and monitors the following parameters:

• Donor Pre-donation Platelet Count: Ensures the donor has a safe baseline platelet count (typically greater than 150,000/µL) before starting the procedure.
• Donor Hemoglobin and Hematocrit Levels: Verifies that the donor is not anemic and can safely undergo the apheresis process.
• Hepatitis B Surface Antigen (HBsAg): Screening to ensure the donor is negative for active Hepatitis B infection.
• Hepatitis C Virus (HCV) Antibodies: Screening to prevent the transmission of Hepatitis C to the recipient.
• Human Immunodeficiency Virus (HIV 1/2) Antibodies and Antigen: Mandatory screening to ensure the safety of the blood product.
• Syphilis (VDRL/TPHA): Screening to detect Treponema pallidum infection in the donor.
• Malaria Parasite (MP): Screening to rule out active plasmodium infection.
• Donor Blood Grouping (ABO and Rh typing): Ensures immunological compatibility between the donor and the recipient.
• Total Platelet Yield: Measures the absolute number of platelets collected in the final product (target is usually greater than 3.0 x 10^11 platelets).
• Product Volume: Evaluates the total volume of the collected platelet concentrate, typically ranging from 200 to 300 mL.
• Residual White Blood Cell (WBC) Count: Evaluates the leukoreduction efficiency to ensure the product contains minimal WBCs, reducing febrile non-hemolytic transfusion reactions.
• Product pH Level: Monitored during quality control to ensure the viability and metabolic health of the stored platelets.
• Bacterial Contamination Screening: Ensures the collected unit is sterile and free from bacterial pathogens before transfusion.
• Donor Post-donation Platelet Count: Evaluated in specific cases to ensure the donor’s post-procedure platelet levels remain within a safe physiological range.
• Donor Total Serum Calcium: Monitored indirectly to manage and prevent citrate-induced hypocalcemia during the procedure.
• Donor Vital Signs: Continuous monitoring of blood pressure, heart rate, and temperature throughout the apheresis process.
• Anticoagulant-to-Blood Ratio: The cell separator automatically calculates and regulates the infusion of acid citrate dextrose (ACD) to prevent clotting in the machine circuit.
• Flow Rate of Blood: Monitors the speed of blood extraction and return to maintain donor hemodynamic stability.
• Centrifugal Speed (RPM): The automated system optimizes separation speed to maximize platelet extraction while protecting red blood cells from hemolysis.
• HLA Compatibility (when requested): Evaluates human leukocyte antigen matching for highly refractory patients.

Turnaround Time and Report Access at Chughtai Lab

At Chughtai Lab, we understand that patients requiring Single Donor Platelets (SDP) are often in critical clinical conditions where time is of the essence. The donor screening process, which includes high-sensitivity testing for infectious diseases (HIV, HBV, HCV, Syphilis, and Malaria), is prioritized and typically completed within 4 to 6 hours of sample collection. Once the donor is cleared, the plateletpheresis procedure itself takes approximately 60 to 90 minutes. The therapeutic platelet unit is then immediately processed, labeled, and made available for transfusion. Chughtai Lab provides seamless digital access to all donor screening reports through our official website and the Chughtai Lab mobile application. Patients, families, and attending physicians can view and download reports in real-time, facilitating rapid clinical decision-making and immediate transfusion planning at the hospital.

Platelets by Cell Separator Findings Overview

The following table outlines the key parameters evaluated during the Platelets by Cell Separator (Single Donor Platelet) procedure at Chughtai Lab, comparing normal donor/product values with potential abnormal findings that require clinical intervention or donor deferral:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Donor Pre-donation Platelet Count	150,000 to 450,000 cells/µL	Less than 150,000 cells/µL (Donor deferred due to thrombocytopenia)
Donor Hemoglobin Level	Greater than or equal to 12.5 g/dL	Less than 12.5 g/dL (Donor deferred due to anemia)
Infectious Disease Screening	Non-reactive / Negative for all pathogens (HIV, HBV, HCV, Syphilis, Malaria)	Reactive / Positive for any pathogen (Donor deferred, product discarded, donor referred for treatment)
Total Platelet Yield in Product	Greater than or equal to 3.0 x 10^11 platelets per unit	Less than 3.0 x 10^11 platelets (Sub-therapeutic yield, may require additional units)
Residual WBC Count (Leukoreduction)	Less than 5.0 x 10^6 cells per unit	Elevated WBC count (Increased risk of febrile transfusion reactions and HLA alloimmunization)
Product pH (at end of storage)	6.4 to 7.4	Less than 6.4 (Indicates poor platelet viability and lactic acidosis in the bag)
Bacterial Culture of Product	No growth / Sterile	Bacterial growth detected (Product discarded immediately due to septic transfusion risk)
Donor Post-donation Platelet Count	Greater than 100,000 cells/µL	Less than 100,000 cells/µL (Requires monitoring; temporary deferral from future donations)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Platelets by Cell Separator?

• State-of-the-Art Blood Bank Facilities: Chughtai Lab operates a highly advanced, fully equipped blood bank system that adheres to international transfusion guidelines.
• Automated Apheresis Technology: We utilize modern, FDA-approved cell separator machines that maximize platelet yield while ensuring donor comfort and safety.
• Qualified Hematologists and Specialists: Every plateletpheresis procedure is supervised by experienced consultant hematologists and trained medical officers.
• Rigorous Donor Screening: We prioritize recipient safety by conducting comprehensive infectious disease screening using highly sensitive chemiluminescence assays.
• Strict Quality Control: Our laboratory strictly monitors platelet yield, pH, and leukoreduction levels to deliver premium-quality therapeutic units.
• Safe and Sterile Environment: We use strictly single-use, sterile disposable apheresis kits, completely eliminating any risk of cross-contamination or infection for the donor.
• Convenient Online Report Access: Recipients and physicians can easily track donor screening results and product availability through the Chughtai Lab mobile app and online portal.
• Widespread Diagnostic Network: With a presence across Pakistan, Chughtai Lab provides unmatched accessibility and support for emergency platelet requirements.